stockrow
Friday 6 November 2026
Export BIO.B’s income statement to Excel — free account
Bio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
379.50
15.35
+4.22%
Follow BIO.B
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
11.12 | 0.00 | 0.00 | 0.00 | 5.07 | 4.49 | 6.27 | 18.88 | 61.72 | 190.78 |
Piotroski F-Score |
5 | 6 | 6 | 4 | 3 | 7 | 5 | 5 | 5 | 4 |
P/S ratio |
3.28 | 3.58 | 3.51 | 4.30 | 7.38 | 6.71 | 4.77 | 3.00 | 3.27 | 2.61 |
Altman Z-Score |
3.24 | 3.78 | 3.19 | 3.44 | 4.55 | 4.76 | 4.47 | 4.20 | 4.77 | 4.22 |
P/FCF ratio |
22.49 | 31.49 | 42.49 | 143.80 | 40.00 | 35.61 | 29.95 | 42.89 | 0.00 | 72.05 |
Altman Z″-Score (non-manufacturers) |
6.54 | 7.04 | 6.57 | 6.49 | 6.64 | 6.66 | 6.14 | 6.53 | 6.14 | 6.12 |
Beneish M-Score |
(2.29) | (3.84) | (2.89) | (4.47) | (1.40) | (0.99) | (1.55) | (2.32) | (2.18) | (2.77) |
P/Operating CF |
51.37 | 73.97 | 115.62 | 151.40 | 126.21 | 58.06 | 69.02 | 65.35 | 101.90 | 56.91 |
P/B ratio |
1.14 | 1.40 | 1.07 | 1.25 | 1.58 | 1.73 | 1.92 | 1.71 | 2.41 | 2.09 |
Price to Tangible BV |
1.26 | 1.57 | 1.17 | 1.36 | 1.65 | 1.82 | 2.06 | 1.87 | 3.14 | 2.78 |
EV/Sales |
3.15 | 3.40 | 3.35 | 4.09 | 7.08 | 6.33 | 4.48 | 2.82 | 3.12 | 2.41 |
EV/EBITDA |
172.31 | 32.43 | 26.50 | 23.74 | 41.37 | 38.23 | 45.06 | 0.00 | 29.92 | 30.04 |
EV/Operating CF |
15.28 | 19.16 | 23.88 | 58.92 | 30.92 | 27.54 | 22.60 | 22.60 | 64.72 | 23.06 |
EV/FCF |
21.59 | 29.90 | 40.62 | 136.67 | 38.39 | 33.57 | 28.10 | 40.33 | (610.54) | 66.58 |
Quick Ratio |
3.87 | 4.53 | 4.02 | 4.03 | 1.91 | 2.24 | 1.67 | 2.76 | 2.44 | 2.58 |
Current Ratio |
5.62 | 6.48 | 5.83 | 5.55 | 2.92 | 3.39 | 2.41 | 4.49 | 3.93 | 3.91 |
Net Debt/EBITDA |
(7.15) | (1.72) | (1.22) | (1.24) | (1.73) | (2.33) | (2.96) | 3.98 | (2.73) | (7.36) |
Debt/Assets |
11.37% | 12.83% | 9.75% | 8.87% | 0.06% | 0.11% | 5.49% | 7.83% | 10.18% | 11.28% |
Debt/Equity |
0.16 | 0.18 | 0.14 | 0.12 | 0.00 | 0.00 | 0.08 | 0.11 | 0.15 | 0.17 |
Asset Turnover |
0.26 | 0.24 | 0.21 | 0.18 | 0.19 | 0.24 | 0.34 | 0.46 | 0.53 | 0.55 |
Operating CF/Net income |
0.70 | (0.25) | (0.59) | (0.05) | 0.16 | 0.15 | 0.26 | 0.78 | 0.85 | 8.31 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
0.96 | 5.50 | 6.84 | 12.67 | 322.59 | 19.27 | 9.81 | (4.31) | 5.18 | 2.38 |
| 10.84% | (24.09%) | (6.94%) | (31.14%) | 36.11% | 48.79% | 35.98% | 10.52% | 4.44% | 1.03% | |
| 7.62% | (17.03%) | (4.94%) | (23.18%) | 27.65% | 36.36% | 25.83% | 7.40% | 3.01% | 0.69% | |
ROIC |
0.41% | 2.75% | 2.54% | 3.34% | 2.44% | 2.96% | 2.83% | (1.79%) | 2.86% | 1.61% |
Return on Tangible Assets |
25.94% | (59.67%) | (20.86%) | (117.48%) | 233.60% | 190.74% | 99.14% | 17.57% | 6.21% | 1.40% |
Average Days of Receivables |
65.08 | 64.35 | 66.82 | 64.43 | 52.90 | 60.14 | 62.00 | 62.57 | 78.55 | 65.71 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 8.92% | 8.55% | 8.77% | 8.70% | 11.58% | 9.95% |
Selling, General and Administrative Expense of Revenue |
32.68% | 31.72% | 31.51% | 29.54% | 30.01% | 31.38% | 35.67% | 36.46% | 37.35% | 39.39% |
Intangible Assets out of Total Assets |
0.07 | 0.08 | 0.06 | 0.05 | 0.03 | 0.04 | 0.05 | 0.06 | 0.16 | 0.17 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.03) | 0.03 | (0.05) | (0.06) | (0.10) | (0.06) | (0.01) | 0.06 | 0.09 | 0.11 |
Graham Number |
414.65 | 0.00 | 0.00 | 0.00 | 1,213.40 | 977.42 | 505.67 | 192.17 | 92.64 | 43.50 |
Earnings Yield |
9.00% | (19.96%) | (6.69%) | (29.98%) | 19.73% | 22.28% | 15.94% | 5.30% | 1.62% | 0.52% |
Free Cash Flow Yield |
4.45% | 3.18% | 2.35% | 0.70% | 2.50% | 2.81% | 3.34% | 2.33% | (0.16%) | 1.39% |
Revenue per Share |
94.75 | 90.97 | 91.45 | 94.08 | 97.97 | 85.52 | 77.46 | 76.73 | 72.84 | 70.25 |
Operating CF per Share |
19.52 | 16.13 | 12.84 | 6.53 | 22.44 | 19.65 | 15.34 | 9.57 | 3.51 | 7.34 |
Capex per Share |
(5.78) | (5.87) | (5.36) | (3.83) | (4.48) | (3.53) | (3.00) | (4.21) | (3.88) | (4.80) |
Free Cash Flow per Share |
13.74 | 10.27 | 7.48 | 2.70 | 17.96 | 16.12 | 12.34 | 5.36 | (0.37) | 2.54 |
Cash per Share |
56.51 | 59.00 | 55.21 | 60.31 | 29.35 | 33.48 | 37.54 | 28.50 | 25.65 | 28.67 |
Shareholders Equity per Share |
273.40 | 232.84 | 299.26 | 322.82 | 458.76 | 331.90 | 192.84 | 134.75 | 98.81 | 87.61 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
273.40 | 232.84 | 299.26 | 322.82 | 458.76 | 331.90 | 192.84 | 134.75 | 98.81 | 87.61 |
Free Cash Flow |
374.70 | 289.70 | 218.40 | 80.30 | 535.77 | 479.89 | 368.31 | 159.98 | (10.90) | 74.89 |
Working Capital |
2,389.20 | 2,562.50 | 2,525.50 | 2,589.27 | 1,309.54 | 1,508.30 | 1,274.66 | 1,572.68 | 1,473.95 | 1,373.20 |
Capital Expenditures |
(157.50) | (165.50) | (156.50) | (114.10) | (133.69) | (105.08) | (89.58) | (125.51) | (115.04) | (141.17) |
Net Current Asset Value |
(216.70) | 235.50 | (509.60) | (728.44) | (2,123.68) | (952.84) | (73.65) | 432.74 | 633.89 | 573.18 |
EV/EBIT |
172.31 | 32.43 | 26.50 | 23.74 | 41.37 | 38.23 | 45.06 | 0.00 | 56.52 | 89.42 |
Capex to Sales |
0.06 | 0.06 | 0.06 | 0.04 | 0.05 | 0.04 | 0.04 | 0.05 | 0.05 | 0.07 |
Price to Operating Income |
179.46 | 34.15 | 27.73 | 24.97 | 43.10 | 40.57 | 48.03 | 0.00 | 59.25 | 96.77 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
3.67% | 3.07% | 1.89% | 0.64% | 3.68% | 4.41% | 5.04% | 3.01% | (0.26%) | 1.94% |
Accounts Receivable Turnover |
5.66 | 5.45 | 5.43 | 6.10 | 6.93 | 6.27 | 5.89 | 5.34 | 5.16 | 5.42 |
Accounts Payable Turnover |
9.89 | 8.90 | 8.90 | 8.92 | 9.13 | 8.99 | 9.19 | 8.28 | 7.25 | 7.28 |
Inventory Turnover |
1.66 | 1.54 | 1.66 | 1.91 | 2.15 | 1.88 | 1.85 | 1.81 | 1.74 | 1.83 |
Average Days of Payables |
37.87 | 37.59 | 42.42 | 39.91 | 40.34 | 45.95 | 37.04 | 41.92 | 50.74 | 52.26 |
Days of Inventory on Hand |
217.45 | 233.58 | 228.95 | 212.61 | 162.61 | 205.03 | 191.73 | 199.85 | 223.25 | 206.09 |
Average Receivables |
456.55 | 470.75 | 491.82 | 459.09 | 421.48 | 406.05 | 392.56 | 428.65 | 418.60 | 381.92 |
Average Payables |
125.65 | 133.45 | 139.82 | 138.49 | 140.70 | 123.23 | 114.73 | 128.82 | 134.15 | 127.75 |
Average Inventory |
750.35 | 770.25 | 749.91 | 645.78 | 597.25 | 588.13 | 568.91 | 589.31 | 559.88 | 507.59 |
Average Assets |
9,970.30 | 10,831.60 | 12,900.39 | 15,650.53 | 15,386.01 | 10,490.74 | 6,809.96 | 4,942.04 | 4,061.76 | 3,780.11 |
Average Common Equity |
7,011.45 | 7,655.25 | 9,178.23 | 11,650.25 | 11,782.59 | 7,817.50 | 4,887.69 | 3,475.29 | 2,754.71 | 2,534.83 |
Columns are period end dates · fundamentals updated 4 Nov 2026